RxDoctor Payments Data

William McLarty, MD

Psychiatry · Smyrna, GANPI 1114080520

Payments from drug & device makers

$1,705in general payments, 2019–2025

Across 98 payments — averaging $17.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$526
  • AbbVie$322
  • Vanda Pharmaceuticals Inc.$216
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$189
  • Otsuka America Pharmaceutical, Inc.$184
  • Avanir Pharmaceuticals, Inc.$57
  • plus $212 from 10 others

What the payments were for

  • Food & beverage$1,67598%
  • Education$302%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,705 in reported general payments places this provider in the 70th percentile of 900 psychiatry providers in Georgia.

See all psychiatry providers in Georgia

Medicare billing

Part B allowed, 2024
$30,053
Medicare patients
68
Services billed
381

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RexultiBrexpiprazole40$103,914
TrintellixVortioxetine Hydrobromide22$14,466
Aripiprazole86$10,003
Ambien CrZolpidem Tartrate11$7,131
Lurasidone Hcl13$4,314
Vilazodone Hcl13$3,894
Quetiapine Fumarate225$3,606
Ziprasidone Hcl41$2,613
Buprenorphine Hcl44$2,592
Divalproex Sodium ErDivalproex Sodium35$2,497
Bupropion Hcl SrBupropion Hcl138$2,376
Alprazolam442$2,375
Bupropion XlBupropion Hcl97$2,316
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl12$2,109
Venlafaxine Hcl ErVenlafaxine Hcl106$2,060

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$184$103,91440 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$13$14,46622 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 900 psychiatry providers in Georgia.

Other psychiatry in Smyrna

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →